Ripretinib [RIP1]

Ripretinib for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant, or internally accredited oncology specialty trainee, specifically trained and assessed in the use of systemic anti-cancer therapy.
2. The patient has histologically confirmed metastatic or unresectable gastrointestinal stromal tumour (GIST).
3. The patient has a performance status of 0-2.
4. The patient has had disease progression on, or intolerance to, previous imatinib.
5. The patient has had disease progression on, or intolerance to, previous sunitinib.
6. The patient has had disease progression on, or intolerance to, previous regorafenib
7. Ripretinib will be dosed at 150mg once daily ONLY in line with the Marketing Authorisation
8. Ripretinib is to be continued until loss of clinical benefit or unacceptable toxicity or patient choice to stop treatment, whichever is the sooner.
9. Where a treatment break of more than 6 weeks beyond the expected cycle length is needed for toxicity, a treatment break approval form will be completed to restart treatment, which MUST be approved before treatment with ripretinib is recommenced.
10. Ripretinib is to be otherwise used as set out in its Summary of Product Characteristics (SPCs).

CDF funded From: 31 March 2026

Additional information

Form version: -

CDF Managed Access: No

NICE Technology Appraisal: NA (NA)

Current Form Version

Important

This is an older version of the form. To view the most up to date form follow this link

Older Form Versions

There are previous versions of this form. These may not all be available on this site.